114 related articles for article (PubMed ID: 37086177)
1. Azide-Masked Resiquimod Activated by Hypoxia for Selective Tumor Therapy.
Sun J; Liu Z; Yao H; Zhang H; Zheng M; Shen N; Cheng J; Tang Z; Chen X
Adv Mater; 2023 Jul; 35(29):e2207733. PubMed ID: 37086177
[TBL] [Abstract][Full Text] [Related]
2. Combretastatin A4 Nanodrug-Induced MMP9 Amplification Boosts Tumor-Selective Release of Doxorubicin Prodrug.
Jiang J; Shen N; Ci T; Tang Z; Gu Z; Li G; Chen X
Adv Mater; 2019 Nov; 31(44):e1904278. PubMed ID: 31549774
[TBL] [Abstract][Full Text] [Related]
3. Peptide-guided resiquimod-loaded lignin nanoparticles convert tumor-associated macrophages from M2 to M1 phenotype for enhanced chemotherapy.
Figueiredo P; Lepland A; Scodeller P; Fontana F; Torrieri G; Tiboni M; Shahbazi MA; Casettari L; Kostiainen MA; Hirvonen J; Teesalu T; Santos HA
Acta Biomater; 2021 Oct; 133():231-243. PubMed ID: 33011297
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-activated glutamine antagonist prodrug combined with combretastatin A4 nanoparticles for tumor-selective metabolic blockade.
Zheng M; Xu H; Huang Y; Sun J; Zhang H; Lv Z; Liu Z; Tang Z; Chen X
J Control Release; 2024 Jan; 365():480-490. PubMed ID: 38040341
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral combination therapy with poly(I:C) and resiquimod synergistically triggers tumor-associated macrophages for effective systemic antitumoral immunity.
Anfray C; Mainini F; Digifico E; Maeda A; Sironi M; Erreni M; Anselmo A; Ummarino A; Gandoy S; Expósito F; Redrado M; Serrano D; Calvo A; Martens M; Bravo S; Mantovani A; Allavena P; Andón FT
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531246
[TBL] [Abstract][Full Text] [Related]
6. Selectively Potentiating Hypoxia Levels by Combretastatin A4 Nanomedicine: Toward Highly Enhanced Hypoxia-Activated Prodrug Tirapazamine Therapy for Metastatic Tumors.
Yang S; Tang Z; Hu C; Zhang D; Shen N; Yu H; Chen X
Adv Mater; 2019 Mar; 31(11):e1805955. PubMed ID: 30680816
[TBL] [Abstract][Full Text] [Related]
7. Radiation-Activated Resiquimod Prodrug Nanomaterials for Enhancing Immune Checkpoint Inhibitor Therapy.
Sun J; Yao H; Ren X; Cui L; Liu L; Wang G; Tang Z
Nano Lett; 2024 Mar; 24(9):2921-2930. PubMed ID: 38411094
[TBL] [Abstract][Full Text] [Related]
8. Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
Thauvin C; Widmer J; Mottas I; Hocevar S; Allémann E; Bourquin C; Delie F
Eur J Pharm Biopharm; 2019 Jun; 139():253-261. PubMed ID: 30981947
[TBL] [Abstract][Full Text] [Related]
9. Development of thermosensitive resiquimod-loaded liposomes for enhanced cancer immunotherapy.
Zhang H; Tang WL; Kheirolomoom A; Fite BZ; Wu B; Lau K; Baikoghli M; Raie MN; Tumbale SK; Foiret J; Ingham ES; Mahakian LM; Tam SM; Cheng RH; Borowsky AD; Ferrara KW
J Control Release; 2021 Feb; 330():1080-1094. PubMed ID: 33189786
[TBL] [Abstract][Full Text] [Related]
10. Enhanced anti-PD-1 therapy in hepatocellular carcinoma by tumor vascular disruption and normalization dependent on combretastatin A4 nanoparticles and DC101.
Bao X; Shen N; Lou Y; Yu H; Wang Y; Liu L; Tang Z; Chen X
Theranostics; 2021; 11(12):5955-5969. PubMed ID: 33897892
[TBL] [Abstract][Full Text] [Related]
11. Engineering kinetics of TLR7/8 agonist release from bottlebrush prodrugs enables tumor-focused immune stimulation.
Bhagchandani SH; Vohidov F; Milling LE; Tong EY; Brown CM; Ramseier ML; Liu B; Fessenden TB; Nguyen HV; Kiel GR; Won L; Langer RS; Spranger S; Shalek AK; Irvine DJ; Johnson JA
Sci Adv; 2023 Apr; 9(16):eadg2239. PubMed ID: 37075115
[TBL] [Abstract][Full Text] [Related]
12. Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors.
Bahmani B; Gong H; Luk BT; Haushalter KJ; DeTeresa E; Previti M; Zhou J; Gao W; Bui JD; Zhang L; Fang RH; Zhang J
Nat Commun; 2021 Mar; 12(1):1999. PubMed ID: 33790276
[TBL] [Abstract][Full Text] [Related]
13. Nitro-chloromethylbenzindolines: hypoxia-activated prodrugs of potent adenine N3 DNA minor groove alkylators.
Wilson WR; Stribbling SM; Pruijn FB; Syddall SP; Patterson AV; Liyanage HD; Smith E; Botting KJ; Tercel M
Mol Cancer Ther; 2009 Oct; 8(10):2903-13. PubMed ID: 19808982
[TBL] [Abstract][Full Text] [Related]
14. Co-administration of combretastatin A4 nanoparticles and anti-PD-L1 for synergistic therapy of hepatocellular carcinoma.
Zhao B; Dong Z; Liu W; Lou F; Wang Q; Hong H; Wang Y
J Nanobiotechnology; 2021 May; 19(1):124. PubMed ID: 33933077
[TBL] [Abstract][Full Text] [Related]
15. Mesoporous Silica Nanoparticles as pH-Responsive Carrier for the Immune-Activating Drug Resiquimod Enhance the Local Immune Response in Mice.
Wagner J; Gößl D; Ustyanovska N; Xiong M; Hauser D; Zhuzhgova O; Hočevar S; Taskoparan B; Poller L; Datz S; Engelke H; Daali Y; Bein T; Bourquin C
ACS Nano; 2021 Mar; 15(3):4450-4466. PubMed ID: 33648336
[TBL] [Abstract][Full Text] [Related]
16. Combretastatin A4 Nanoparticles Combined with Hypoxia-Sensitive Imiquimod: A New Paradigm for the Modulation of Host Immunological Responses during Cancer Treatment.
Shen N; Wu J; Yang C; Yu H; Yang S; Li T; Chen J; Tang Z; Chen X
Nano Lett; 2019 Nov; 19(11):8021-8031. PubMed ID: 31558024
[TBL] [Abstract][Full Text] [Related]
17. Multifunctional nanoparticles based on a polymeric copper chelator for combination treatment of metastatic breast cancer.
Zhou P; Qin J; Zhou C; Wan G; Liu Y; Zhang M; Yang X; Zhang N; Wang Y
Biomaterials; 2019 Mar; 195():86-99. PubMed ID: 30623789
[TBL] [Abstract][Full Text] [Related]
18. Enhancing the Release Efficiency of a Molecular Chemotherapeutic Prodrug by Photodynamic Therapy.
Yuan J; Zhou QH; Xu S; Zuo QP; Li W; Zhang XX; Ren TB; Yuan L; Zhang XB
Angew Chem Int Ed Engl; 2022 Aug; 61(33):e202206169. PubMed ID: 35688800
[TBL] [Abstract][Full Text] [Related]
19. Co-administration of combretastatin A4 nanoparticles and sorafenib for systemic therapy of hepatocellular carcinoma.
Wang Y; Yu H; Zhang D; Wang G; Song W; Liu Y; Ma S; Tang Z; Liu Z; Sakurai K; Chen X
Acta Biomater; 2019 Jul; 92():229-240. PubMed ID: 31100462
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in hypoxia-activated compounds for cancer diagnosis and treatment.
Yuan X; Xie Z; Zou T
Bioorg Chem; 2024 Mar; 144():107161. PubMed ID: 38306826
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
